The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3–30)NH2, was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3–30)NH2 to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF), and lipid metabolism in humans. Eight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on three different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GIP, GIP(3–30)NH2, or both GIP and GIP(3–30)NH2. During infusion of GIP(3–30)NH2 alone and in combination with GIP, insulin levels and the total glucose amount infused to maintain the clamp were lower than during GIP alone. In addition, ATBF remained constant during the antagonist and increased only slightly in combination with GIP, whereas it increased fivefold during GIP alone. Adipose tissue triacylglyceride (TAG) and glucose uptake decreased, and the free fatty acid/glycerol ratio increased during the antagonist alone and in combination with GIP. The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect of the antagonist on the incretin effect of GIP. In addition, the antagonist inhibited GIP-induced increase in ATBF and decreased the adipose tissue TAG uptake, indicating that GIP also plays a crucial role in lipid metabolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Previous in vitro and animal studies have shown that GIP may play a role in obesity and have suggested that GIP receptor may represent a target for the prevention and treatment of obesity (29,30).”
Self-citationAdipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationFrayn, K. N., Shadid, S., Hamlani, R., Humphreys, S. M., Clark, M. L., Fielding, B. A., Boland, O., & Coppack, S. W. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.3.e308 · Cited by 188
Incretin Hormone and Insulin Responses to Oral Versus Intravenous Lipid Administration in Humans
Lindgren, O., Carr, R. D., Deacon, C. F., Holst, J. J., Pacini, G., Mari, A., & Ahrén, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0266 · Cited by 188
Self-citationAsmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010) · Diabetes · doi:10.2337/db10-0098 · Cited by 184 · cited 4×
“We have previously demonstrated that GIP infusions in the presence of elevated insulin concentrations increased ATBF and stimulated triacylglyceride (TAG) deposition in adipose tissue in lean humans (1), suggesting that GIP together with insulin are controllers of postprandial fat deposition.”
BackgroundMethodResultInfluentialSelf-citationRegulation of human subcutaneous adipose tissue blood flow
Frayn, K. N., & Karpe, F. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.200 · Cited by 173
Summers, L. K. M., Samra, J. S., Humphreys, S. M., Morris, R. J., & Frayn, K. N. (1996) · Clinical Science · doi:10.1042/cs0910679 · Cited by 167
Tseng, C. C., Kieffer, T. J., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119060 · Cited by 151
Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 114
Self-citation
Cited by
Items 101–131 of 131
Chu, N. H. S., He, J., Leung, K. H. T., Ronald, C. W., Lee, J. Y. S., Varney, J. E., Chan, J. C. N., Muir, J. G., & Chow, E. (2023) · Nutrients · doi:10.3390/nu15245070 · Cited by 6
“These changes in the metabolic and hormonal milieu can systemically regulate gluconeogenesis and glycogenolysis in the liver and lipolysis from adipose tissues [22,63,64].”
BackgroundMontastier, É., Ye, R. Z., Noll, C., Amrani, M., Frisch, F., Fortin, M., Bouffard, L., Phoenix, S., Sarrhini, O., Cunnane, S. C., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177563 · Cited by 6
Hypoglycemic and hypolipidemic effects of Lippia origanoides Kunth in diabetic rats
Miranda, V. C., Pereira, Y. L. G., da Paz, A. P. S., de Souza, K. R., da Silva, M. C. F., Muto, N. A., Monteiro, P. R., Santos, A. V., Hamoy, M., de Medeiros, M. D. G. F., et al. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4162 · Cited by 6
Kahles, F., Rau, M., Reugels, M., Foldenauer, A. C., Mertens, R. W., Arrivas, M. C., Schröder, J. H., Idel, P., Moellmann, J., van der Vorst, E. P. C., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01454-3 · Cited by 5
“Introduction The gut incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide) are secreted by enteroendocrine cells following nutrient intake leading to insulin secretion and glucose control [1, 2].”
BackgroundNovel approaches to pharmacological management of type 2 diabetes in Japan
Kaneko, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1974401 · Cited by 6
“ing carbohydrate/fat degradation in adipose tissue, and thus supports fat accumulation [46].”
BackgroundRole of endogenous incretins in the regulation of postprandial lipoprotein metabolism
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Sihlbom, C., Thorsell, A., Andersson, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1187 · Cited by 4
Self-citationKrogh, L. S. L., Helsted, M. M., Englund, A., Bergmann, N. C., Skov‐Jeppesen, K., Nielsen, C. K., Hansen, C. P., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70186 · Cited by 4
“6 When infused intravenously, GIP causes acute reduction in bone resorption assessed by carboxy-terminal collagen crosslinks (CTX), 3 and it has been shown that endogenous GIP is responsible for 22 – 25% of the postprandial CTX suppression.”
Self-citationDual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence
Wardeh, R., Elbo-Iswadi, T. H., Alsharayri, H. M. H., Rashid, F., Alhashemi, N., & Bashier, A. M. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1775966 · Cited by 5
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“At the pancreatic level, GIP enhances insulin secretion [213–217], which helps regulate postprandial blood glucose levels by promoting the disposal of nutrients into adipose tissues [202,218].”
Incretin Signaling Neighborhoods and Adverse Drug Reactions
Wright, S. C., Lindquist, P., ROSENKILDE, M. M., & Lauschke, V. M. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-015046 · Cited by 3
Self-citationGlucose sensing and homeostasis by adipocyte GPCR
Hasan, N., & Chhabra, K. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1657747 · Cited by 3
The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism
Lin, A., Kitaura, H., Ohori, F., Marahleh, A., Ma, J., Fan, Z., Narita, K., Murakami, K., & KANETAKA, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020600 · Cited by 2
“The naturally occurring peptide GIP(3–30)NH 2 acts as a highly selective GIPR antagonist and has been shown to counteract GIP-induced insulin secretion, adipose tissue perfusion, and triglyceride deposition [61,62].”
Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
“37,38 Animal experiments have shown that GIP promotes the hydrolysis of chylomicrons and other lipoproteins by increasing the activity of lipoprotein lipase (LPL), which facilitates the absorption and storage of triglycerides in adipose tissue, while reducing plasma levels of triglycerides and free…”
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Safety of native glucose-dependent insulinotropic polypeptide in humans
Helsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171214 · Cited by 3
Self-citationCurto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Chu, N. H. S., He, J., Ling, J., Leung, K. S., Ma, R., Lee, J. Y. S., Varney, J. E., Chan, J., Muir, J., & Chow, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.26.513956 · Cited by 1
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Pfeiffer, A. F. H. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0947-2988
“Diabetes 2017; 66: 880–885 [18] Asmar M, Asmar A, Simonsen L et al.”
BackgroundModulating Glycaemia with Cereal Products
Priebe, M. G., Eelderink, C., & Vonk, R. J. (2021) · Wiley eBooks · doi:10.1002/9781118939420.ch14
思想的飞刀:是百无一用还是百发百中——读《影响世界历史的100名著排行榜》
孔庆典 (2006) · 民主与科学
Regional Intestinal Drug Absorption
Gonzalez-Alvarez, M. I., & Dahan, A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3657-6
Xie, C., White, J. B., Huang, W., Horowitz, M., Rayner, C. K., Verjans, J. W. H., Snel, M. F., Psaltis, P. J., & Wu, T. (2026) · Diabetes · doi:10.2337/db25-0980 · Cited by 1
Asmar, M., Bülow, J., Holst, J. J., & Asmar, A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag084
Self-citationKrogh, L. S. L., Hansen, M. B., Bergmann, N. C., Hansen, C. P., Hartmann, B., Holst, J. J., Knop, F. K., Lund, A., & Gasbjerg, L. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70940 · Cited by 1
“…and exogenous GIP inhibit postprandial bone resorption [6], increase blood flow to the intestines [7], as well as increase heart rate and blood pressure [8], and additionally, exogenous GIP increases blood flow to the adipose tissue [9] and plays a role in adipose tissue signalling in mice [10].”
Self-citationIncretin-based therapies: Effects on plasma lipids and potential mechanisms
Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Rasmussen, R. S., Nielsen, S. W., Alstrup, L., Larsson, T. S. W., Hansen, J. K., Pedersen, R. P., Vestergaard, M. B., Haddock, B., Johannesen, H. H., Larsson, H. B. W., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06788-1 · Cited by 1
“Among other functions, GIP infusion, in combination with insulin, markedly increases (fivefold) adipose tissue blood flow (ATBF) and enhances triacylglycerol storage [9, 10] via local capillary recruitment [11].”
Self-citationLiu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Smarkusz-Zarzecka, J., Radziszewska, M., Gofron, K. K., & Ostrowska, L. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10098-7 · Cited by 1
Metadata
- Authors
- Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J.
- Affiliations
- Bispebjerg Hospital (DK)
- University of Copenhagen (DK)
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
- Corresponding author
- Asmar, Meena
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-06-30
- Volume
- 66
- Issue
- 9
- Pages
- 2363-2371
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2728467537
- Cited by
- 132
- References
- 32
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 14 · 2023: 8 · 2022: 16 · 2021: 14 · 2020: 14 · 2019: 22 · 2018: 10 · 2017: 2
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor antagonist, incretin effect, adipose tissue blood flow, adipose tissue glucose uptake, lipid metabolism, glucose metabolism, insulin secretion
- MeSH terms
- Adipose Tissue, Adult, Blood Glucose, Fatty Acids, Nonesterified, Gastric Inhibitory Polypeptide, Glucose, Glycerol, Humans, Male, Peptide Fragments, Receptors, Gastrointestinal Hormone, Triglycerides, Glucose Clamp Technique, Cross-Over Studies, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.